Company news

Skye Bioscience, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Skye Bioscience Appoints Chris Twitty, PhD, as Chief Scientific Officer

December 12, 2022

Skye Bioscience Submits Investigational New Drug Application for SBI-100 Ophthalmic Emulsion to FDA

November 16, 2022

Skye Bioscience Initiates First-in-Human Phase 1 Clinical Trial for SBI-100

November 15, 2022

Skye Bioscience Closes Acquisition of Emerald Health Therapeutics

November 9, 2022

Skye Bioscience Stockholders Vote in Favor of Arrangement Agreement with Emerald Health Therapeutics, Inc.

September 29, 2022

Skye Bioscience Completes Drug Production for Phase 1 Clinical Study

September 19, 2022

Skye Bioscience Files Definitive Proxy Statement and Announces Stockholder Meeting Date

August 31, 2022

Skye Bioscience Selects NextPharma as Phase 2 Contract Drug Manufacturer

July 20, 2022

Skye Bioscience Updates Phase 1 Timeline

July 19, 2022

Skye Bioscience Receives Australian Ethics Committee Approval to Start First-in-Human Phase 1 Study of SBI-100 Ophthalmic Emulsion

June 29, 2022

Skye Bioscience Expands Cannabinoid Pharmaceutical Innovation Program with Leading Cannabinoid Medicinal Chemistry Groups

June 6, 2022

Skye Bioscience Signs Arrangement Agreement with Emerald Health Therapeutics

May 11, 2022

Skye Bioscience Engages Clinical Trial Site for Phase 1 Study in Agreement with CMAX Clinical Research

April 27, 2022

Skye Bioscience Retains Novotech as CRO for Phase 1 Trial of Glaucoma Drug Candidate

March 2, 2022

Skye Bioscience Reports Positive Results for SBI-100 in GLP Toxicology Study

February 15, 2022

Skye Bioscience Reports Potential Neuroprotective Benefit of SBI-100 In Preclinical Glaucoma Model

January 31, 2022

Skye Bioscience Expands Board of Directors with the Appointment of Life Sciences Executive Keith W. Ward, PhD

December 14, 2021

Skye Bioscience Establishes New Cannabinoid Pharmaceutical Innovation Program

October 11, 2021

Skye Bioscience Appoints Head of Regulatory Affairs & Quality Assurance and Senior Director of Research & Development

October 6, 2021

Skye Bioscience Appoints Kaitlyn Arsenault as Chief Financial Officer

October 4, 2021

Skye Bioscience Announces Closing of $7.0 Million Registered Direct Offering

September 28, 2021

Skye Bioscience Announces $7.0 Million Registered Direct Offering

September 26, 2021

Skye Bioscience Announces THCVHS Late-Breaking Preclinical Abstracts Selected by American Association of Pharmaceutical Scientists Meeting PharmSci 360

September 20, 2021

Skye Bioscience Announces Special Virtual Investor Presentation

September 13, 2021

Skye Bioscience Completes THCVHS IND-enabling In Vitro Genotoxicity Studies

August 9, 2021

Skye Bioscience Appoints Biotech Executive Praveen Tyle, Ph.D. to Board of Directors

July 25, 2021

Skye Bioscience Expands Clinical Advisory Board with the Appointment of Ophthalmology Expert Dr. Miguel González-Andrades

June 9, 2021

Skye Bioscience Completes CMC and GLP Production for THCVHS Lead Program

April 21, 2021

Skye Bioscience Appoints Cannabinoid Science Experts Giovanni Appendino, PhD and Eduardo Muñoz, MD, PhD to Scientific Advisory Board

March 7, 2021

← Newer news releases

Calls

The 5 newest of 6 calls. Every call is listed under its year.

Decks

The 5 newest of 41 decks. Every deck is listed under its year.